Wild-type p53 activates transcription in vitro
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 protein is an important determinant in human cancer and regulates the growth of cells in culture. It is known to be a sequence-specific DNA-binding protein with a powerful activation domain, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The tumor-suppressor protein, p53, plays a central role in the cellular response to UV-induced DNA damage/repair (13).”
From Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism (2010) · cites this paper as [13]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
How eukaryotic transcriptional activators work
Ptashne, M. (1988) · Nature · doi:10.1038/335683a0 · Cited by 1,825
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene
Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 619
Research works printed but not linked: 7
- O'Rourke, R. W. et al. Oncogene 5, 1829–1832 (1990).
- Zhu, H., Roy, A. L., Roeder, R. G. & Prywes, R. New Biologist 3, 455–464 (1991).
- Kern, S. E. et al. Oncogene 6, 131–136 (1991).
- Fried, M. & Prives, C. Cancer Cells 4, 1–16 (1986).
- Soussi, T., Caron de Fromentel, C. & May, P. Oncogene 5, 945–952 (1990).
- Murakami, Y., Asano, M., Satake, M. & Ito, Y. Oncogene 5, 5–14 (1990).
- Zambetti, G. P. et al. Genes Dev. (in the press).
Cited by
Items 301–400 of 578
Identification of a novel mouse p53 target gene DDA3
Lo, P., Chen, J.-Y., Lo, W.-C., Chen, B.-F., Hsin, J.-P., Tang, P.-P., & Wang, F.-F. (1999) · Oncogene · doi:10.1038/sj.onc.1203167 · Cited by 49
“…biochemical function of p53 is its activity to modulate the transcription of genes carrying distinct p53 recognition motifs (El-Deiry et al., 1992; Farmer et al., 1992). p53 contains distinctive domains for DNA binding and transactivation (Vogelstein and Kinzler, 1994; Ko and Prives, 1996).”
BackgroundSkin exposure to UVB light induces a skin-brain-gonad axis and sexual behavior
Parikh, R., Sorek, E., Parikh, S., Michael, K., Bikovski, L., Tshori, S., Shefer, G., Mingelgreen, S., Zornitzki, T., Knobler, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109579 · Cited by 42
“In line with this, knock down of p53 has been shown to trigger the DNA damage response in skin keratinocytes that results in peeling of these cells (Farmer et al., 1992; Fields and Jang, 1990; Levine et al., 2006; de Pedro et al., 2018).”
Sun, Y., Mu, Y., Ma, S., Gong, P., Yan, G., Liu, J., Shen, J., & Luo, G. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.10.014 · Cited by 41
Konomoto, T., Fukuda, T., Hayashi, K., Kumazawa, J., & Tsuneyoshi, M. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90393-8 · Cited by 43
Fuchs, B., Hecker, D., & Scheidtmann, K. H. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.0625m.x · Cited by 46
Yamaguchi, M., Hayashi, Y., Matsuoka, S., Takahashi, T., & Matsukage, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18733.x · Cited by 42
p53 and Bax: Putative death factors in taste cell turnover
Zeng, Q., & Oakley, B. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991011)413:1<168::aid-cne12>3.0.co;2-y · Cited by 41
“Hence, the bax gene is a credible p53 target in selected apoptotic pathways (Farmer et al., 1992; Miyashita et al., 1994; Selvakumaran et al., 1994; Sabbatini et al., 1995; Yonish-Rouach et al., 1995).”
BackgroundMann, S. S., & Hammarback, J. A. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19960301)43:5<535::aid-jnr3>3.0.co;2-j · Cited by 51
Field, J. K. (1995) · PubMed Central · Cited by 40
p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome
Quesnel, S., Verselis, S. J., Portwine, C., Garber, J. E., White, M. B., Feunteun, J., Malkin, D. M., & Li, F. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202783 · Cited by 45
“Some p53 mutants have simply lost their growth suppressive properties, but others are thought to inhibit the functions of the wild-type protein in a `dominant negative' fashion through oligomerization (Farmer et al., 1992; Kern et al., 1992).”
BackgroundDuan, W., Gao, L., Wu, X., Zhang, Y., Otterson, G. A., & Villalona-Calero, M. A. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.07.005 · Cited by 42
Tiemann, F., & Deppert, W. (1994) · Journal of Virology · doi:10.1128/jvi.68.5.2869-2878.1994 · Cited by 38
“Binding of large T to p53 eliminates wild-type p53-specific functions such as DNA binding and transactivation (20, 58).”
BackgroundChristman, J. K., CHEN, M., Sheikhnejad, G., Dizik, M., Abileah, S., & Wainfan, E. (1993) · The Journal of Nutritional Biochemistry · doi:10.1016/0955-2863(93)90106-7 · Cited by 38
Choisy, C., Reisdorf, P., & Yonish-Rouach, E. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00238-0 · Cited by 38
Zhu, G. H., Wong, B. C. Y., Ching, C. K., Lai, K. C., & Lam, S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00058-1 · Cited by 38
Shadan, F. F., Cowsert, L. M., & Villarreal, L. P. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.4785-4796.1994 · Cited by 40
“This view is supported by the finding that the SV40 large T antigen, possibly ElA and E1B of adenovirus, and the E6 and E7 proteins of papillomaviruses interact with and inhibit the transactivation (26, 47, 80) and polymerase-primase complex inactivation (10, 23, 24) properties of p53.”
BackgroundRegulation of transcription factor activity during cellular aging
Wheaton, K., Atadja, P. W., & Riabowol, K. T. (1996) · Biochemistry and Cell Biology · doi:10.1139/o96-056 · Cited by 39
“p53 negatively regulates growth by promoting the transcription of growth inhibitory genes such as the 21kDa inhibitor (p21) of cyclin-dependent kinases (CDK; Farmer et al. 1992).”
BackgroundStein, T., Crighton, D., Boyle, J. M., Varley, J. M., & White, R. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205372 · Cited by 47
“It can bind to DNA in a sequence-speci®c fashion and stimulate expression of proximal genes (Bargonetti et al., 1991; Farmer et al., 1992; Kern et al., 1991; Zambetti et al., 1992).”
BackgroundSoussi, T. (1995) · Advances in genome biology · doi:10.1016/s1067-5701(06)80005-7 · Cited by 38
van den Heuvel, S., van Laar, T., The, I., & van der Eb, A. J. (1993) · Journal of Virology · doi:10.1128/jvi.67.9.5226-5234.1993 · Cited by 37
“Several mutant forms of p53 are also thought to inactivate endogenous p53 and have recently been shown to block wt p53-mediated transcriptional activation (13, 24).”
BackgroundRegulation of p53 mediated transactivation by the β‐subunit of protein kinase CK2
Schuster, N., Prowald, A., Schneider, E., Scheidtmann, K., & Montenarh, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00273-2 · Cited by 39
p53 Inhibits DNA Replication In Vitro in a DNA-Binding-Dependent Manner
Miller, S. D., Farmer, G., & Prives, C. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6554 · Cited by 36
Inman, G. J., & Farrell, P. J. (1995) · Journal of General Virology · doi:10.1099/0022-1317-76-9-2141 · Cited by 37
Tiemann, F., Zerrahn, J., & Deppert, W. (1995) · Journal of Virology · doi:10.1128/jvi.69.10.6115-6121.1995 · Cited by 40
“However, since wt p53 complexed to large T has lost at least some of the properties of free wt p53, such as sequence-specific transactivation of p53-responsive genes (11, 38), by this criterion it behaves like a mutant p53.”
BackgroundGualberto, A., Hixon, M. L., Finco, T. S., Perkins, N. D., Nabel, G. J., & Baldwin, A. S. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3450 · Cited by 37
“p53 activates transcription of reporter genes that contain multiple copies of the wild-type p53 binding site (20, 24, 33).”
BackgroundZhou, X., Wang, X. W., Xu, L., Hagiwara, K., Nagashima, M., Wolkowicz, R., Zurer, I., Rotter, V., & Harris, C. C. (1999) · PubMed · Cited by 43
p53 domains: suppression, transformation, and transactivation.
Reed, M. J., Wang, Y., Mayr, G. A., Me, A., Schwedes, J. F., & Tegtmeyer, P. (1993) · Europe PMC (PubMed Central) · Cited by 38
Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein.
Iotsova, V., & Stéhelin, D. (1996) · PubMed · Cited by 37
The Evolution of TP53 Mutations: From Loss-of-Function to Separation-of-Function Mutants.
Miller, M., Shirole, N. H., Tian, R., Pal, D., & Sordella, R. (2016) · PubMed · Cited by 37
Apoptosis and programmed cell death: a role in cerebral ischemia
Charriaut‐Marlangue, C., Remolleau, S., Zouaoui, D., & Ben‐Ari, Y. (1998) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(98)80012-7 · Cited by 36
Dysregulation of cellular membrane homeostasis as a crucial modulator of cancer risk
Erazo‐Oliveras, A., Muñoz‐Vega, M., Salinas, M. L., Wang, X., & Chapkin, R. S. (2022) · FEBS Journal · doi:10.1111/febs.16665 · Cited by 42
Human DDA3 is an oncoprotein down-regulated by p53 and DNA damage
Hsieh, W.-J., Hsieh, S., Chen, C.-C., & Wang, F.-F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.047 · Cited by 34
Human papillomavirus DNA and abnormal p53 expression in carcinoma of the urinary bladder
Kamel, D., Pääkkö, P. K., Pöllänen, R., Vähäkangas, K., Lehto, V., & Soini, Y. (1995) · Apmis · doi:10.1111/j.1699-0463.1995.tb01116.x · Cited by 34
The Prognostic Value of P53 in Superficially Infiltrating Transitional Cell Carcinoma
Vatne, V., Maartmann-Moe, H., & Hostmark, J. G. (1995) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365599509180032 · Cited by 34
Splicing mutations of the p53 gene in human hepatocellular carcinoma.
Lai, M., Chang, H. C., Li, H., Ku, C. K., Chen, P., Sheu, J., Huang, G., Lee, P., & Chen, D. (1993) · PubMed · Cited by 33
Akagi, M., Yasui, W., Akama, Y., Yokozaki, H., Tahara, H., Haruma, K., Kajiyama, G., & Tahara, E. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb00233.x · Cited by 36
Effects of p53 mutation on tumor progression: recent insights from mouse tumor models
Donehower, L. A. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00013-6 · Cited by 34
Sharma, S., Schwarte‐Waldhoff, I., Oberhuber, H., & Schäfer, R. (1993) · PubMed · Cited by 36
Molecular Genetics and Cytogenetics of Sarcomas
Kruzelock, R. P., & Hansen, M. F. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30082-0 · Cited by 37
Duan, W., Ding, H., Subler, M. A., Zhu, W., Zhang, H., Stoner, G. D., Windle, J. J., Otterson, G. A., & Villalona-Calero, M. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205909 · Cited by 33
“…in a ‘dominant-negative’ manner (prior to the outright deletion of the remaining wild-type allele), by forming hetero-oligomeric complexes with it (Farmer et al., 1992; Kern et al., Received 10 January 2002; revised 24 July 2002; accepted 24 July 2002 *Correspondence: MA Villalona-Calero,…”
BackgroundFailure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
Vinyals, A., Peinado, M. A., González-Garrigues, M., Monzó, M., Bonfil, R. D., & Fabra, À. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300786 · Cited by 32
Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation
el-Mahdani, N., Vaillant, J. C., Guiguet, M., Prevot, S., Bertrand, V., Bernard, C., Parc, R., Bereziat, G., & Hermelin, B. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.92 · Cited by 36
Mukhopadhyay, T. K., & Roth, J. A. (1993) · PubMed · Cited by 32
Chen, Y., Chen, P., & Lee, W. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6764 · Cited by 38
Transcriptional Inhibition of p53 by the MLL/MEN Chimeric Protein Found in Myeloid Leukemia
Maki, K., Mitani, K., Yamagata, T., Kurokawa, M., Kanda, Y., Yazaki, Y., & Hirai, H. (1999) · Blood · doi:10.1182/blood.v93.10.3216.410k45_3216_3224 · Cited by 31
Baculovirus p33 Binds Human p53 and Enhances p53-Mediated Apoptosis
Prikhod’ko, G. G., Wang, Y., Freulich, E., Prives, C. L., & Miller, L. K. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1227-1234.1999 · Cited by 31
“The simian virus 40 large tumor antigen binds to the p53 central conserved region and represses its transactivation function (5, 13).”
Backgroundp53 immunohistochemical positivity as a prognostic marker in intracranial tumours
Soini, Y., Niemelä, A., Kamel, D., Herva, R., Bloigu, R., Pääkkö, P. K., & Vähäkangas, K. (1994) · Apmis · doi:10.1111/j.1699-0463.1994.tb05235.x · Cited by 31
“DNA and act as a transcription factor (9, 39).”
BackgroundNihei, T., Sato, N., Takahashi, S., Ishikawa, M., Sagae, S., Kudo, R., Kikuchi, K., & Inoue, A. (1993) · Cancer Letters · doi:10.1016/0304-3835(93)90262-8 · Cited by 31
p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response
Serra, F., Nieto-Aliseda, A., Fanlo, L., Rovirosa, L., Cabrera-Pasadas, M., Lazarenkov, A., Urmeneta, B., Alcalde-Merino, A., Nola, E., Okorokov, A. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46666-1 · Cited by 33
Scotcher, J., Clarke, D. J., Mackay, C. L., Hupp, T. R., Sadler, P. J., & Langridge‐Smith, P. R. R. (2013) · Chemical Science · doi:10.1039/c2sc21702c · Cited by 32
Synthesis of the Chlorofusin Cyclic Peptide: Assignment of the Asparagine Stereochemistry
Desai, P., Pfeiffer, S. S., & Boger, D. L. (2003) · Organic Letters · doi:10.1021/ol036083g · Cited by 30
Lin, C., Kuo, H.-H., Chen, J., Yang, C., & Wang, W.-B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4121 · Cited by 33
Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
Zhang, W., Shay, J. W., & Deisseroth, A. (1993) · PubMed · Cited by 30
The Immunocytochemical Detection of P53 Protein In Cytological Specimens: Technical Considerations
Dowell, S. P., Lane, D. P., & Hall, P. A. (1994) · Cytopathology · doi:10.1111/j.1365-2303.1994.tb00530.x · Cited by 30
Functional analysis of p53 tumor suppressor in yeast
Šmardová, J., Šmarda, J., & Koptíková, J. (2005) · Differentiation · doi:10.1111/j.1432-0436.2005.00028.x · Cited by 41
Yeudall, W. A., Jakus, J., Ensley, J. F., & Robbins, K. C. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199702)18:2<66::aid-mc2>3.0.co;2-o · Cited by 45
Overexpression of bax Associated with Mutations in the Loop-Sheet-Helix Motif of p53
Huang, C., Kohno, N., Inufusa, H., Kodama, K., Taki, T., & Miyake, M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65195-4 · Cited by 29
“p53 protein is a DNA-binding protein, with a sequence-specific DNA-binding region in the core domain.(9,10) Two regions of the core domain of the p53 protein, the loop-sheet-helix motif (codons 273 to 286) and the L3-loop (codons 237 to 250), are considered to play important roles in contact with target DNA.”
BackgroundDoing the right thing: feedback control and p53
Prives, C. L. (1993) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(93)90105-y · Cited by 29
Copurification of Casein Kinase II with Transcription Factor ATF/E4TF3
Wada, T., Takagi, T., Yamaguchi, Y., Kawase, H., Hiramoto, M., Ferdous, A., Takayama, M., Lee, K. A. W., Hurst, H. C., & Handa, H. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.5.876 · Cited by 29
Esposito, F., Tornincasa, M., Federico, A., Chiappetta, G., Pierantoni, G. M., & Fusco, A. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.126 · Cited by 30
RetractedThe function of Drosophila p53 isoforms in apoptosis
Zhang, B., Rotelli, M. D., Dixon, M. J., & Calvi, B. R. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.40 · Cited by 29
P53 Activates Fanconi Anemia Group C Gene Expression
Liebetrau, W., Budde, A., Savoia, A., Grummt, F., & Hoehn, H. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.2.277 · Cited by 28
Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein.
Roemer, K., & Friedmann, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9252 · Cited by 29
Several regions of p53 are involved in repression of RNA polymerase III transcription
Stein, T., Crighton, D., Warnock, L. J., Milner, J., & White, R. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205739 · Cited by 28
“DNA precipitates were left on the plates overnight and then the cells were washed with PBS and cultured for 48 h before harvesting.”
BackgroundInfluentialWild-Type p53 Induces Diverse Effects in 32D Cells Expressing Different Oncogenes
Soddu, S., Blandino, G., Scardigli, R., Martinelli, R., Rizzo, M. G., Crescenzi, M., & Sacchi, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.2.487 · Cited by 29
“The product of the wild-type (wt) p53 gene is a nuclear phosphoprotein that binds DNA (29) and functions as a transcription factor (18).”
BackgroundCyclin E Restores p53 Activity in Contact-Inhibited Cells
Deffie, A. M., Hao, M., Luna, R. M. D. O., Hulboy, D. L., & Lozano, G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3926 · Cited by 31
“Wild-type p53-GAL4 fusion proteins (16, 44, 47), as well as p53 itself (15, 20, 30), activate transcription.”
BackgroundTranscriptional Regulation by p53
Hsu, Y.-S., Tang, F.-M., Liu, W., Chuang, J., Lai, M., & Lin, Y.-S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6966 · Cited by 30
Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53
Rushton, J. J., Jiang, D., Srinivasan, A., Pipas, J. M., & Robbins, P. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5620-5623.1997 · Cited by 27
“Firstly, T antigen can bind directly to the p53 central region and block specific DNA binding (6, 8).”
BackgroundMolecular prognostic factors in bladder cancer
Vet, J. A. M., Debruyne, F. M. J., & Schalken, J. A. (1994) · World Journal of Urology · doi:10.1007/bf00184242 · Cited by 29
The evolution of small DNA viruses of eukaryotes: Past and present considerations
Shadan, F. F., & Villarreal, L. P. (1995) · Virus Genes · doi:10.1007/bf01728663 · Cited by 30
Nucleus ambiguus projections to cardiac ganglia of rat atria: An anterograde tracing study
Cheng, Z., & Powley, T. L. (2000) · The Journal of Comparative Neurology · doi:10.1002/1096-9861(20000904)424:4<588::aid-cne3>3.0.co;2-7 · Cited by 118
Stimulation of Polyomavirus DNA Replication by Wild-Type p53 Through the DNA-Binding Site
Kanda, T., Segawa, K., Ohuchi, N., Mori, S., & Ito, Y. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.4.2651 · Cited by 31
Ungar, S., der Meeren, A. V., Tammilehto, L., Linnainmaa, K., Mattson, K. V., & Gerwin, B. I. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.585 · Cited by 29
Mutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma.
Hieken, T. J., & Gupta, T. K. D. (1996) · PubMed · Cited by 27
The clinical relevance of the p53 tumour suppressor gene*
Dowell, S. P., & Hall, P. A. (1994) · Cytopathology · doi:10.1111/j.1365-2303.1994.tb00409.x · Cited by 30
Metal toxicity and the p53 protein: an intimate relationship
Phatak, V. M., & Muller, P. A. J. (2014) · Toxicology Research · doi:10.1039/c4tx00117f · Cited by 29
Glykofridis, I. E., Knol, J. C., Balk, J. A., Westland, D., Pham, T. V., Piersma, S. R., Lougheed, S. M., Derakhshan, S., Veen, P., Rooimans, M. A., et al. (2021) · eLife · doi:10.7554/elife.61630 · Cited by 26
“Conversely, as a control, deletion of the transcriptional activator TP53 alone (Farmer et al., 1992; Fields and Jang, 1990; Vogelstein and Kinzler, 1992) resulted in downregulation of gene expression (Figure 2—figure supplement 1E, right, volcano plots of differential expression analysis by edgeR).”
BackgroundRiedinger, H., van Betteraey‐Nikoleit, M., & Probst, H. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2243-2252.1999 · Cited by 26
“For SV40 replication in vivo, a p53-dependent pathway can be excluded a priori, since this protein is bound and thus inactivated by the large T antigen (25, 35, 36).”
Backgroundp53: Tumor suppression through control of the cell cycle
Kern, S. E. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90431-6 · Cited by 26
The status of p53 in the metastatic progression of colorectal cancer
Heide, I., Thiede, C., Sonntag, T., de Kant, E., Neubauer, A., Jonas, S., Peter, F. J., Neuhaus, P., Herrmann, R., Huhn, D., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00118-4 · Cited by 26
Hansen, S., Midgley, C., Lane, D. P., Freeman, B., Morimoto, R. I., & Hupp, T. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30922 · Cited by 31
Gillet, R., Grimber, G., Bennoun, M., de Fromentel, C. C., Briand, P., & Joulin, V. (2000) · Oncogene · doi:10.1038/sj.onc.1203671 · Cited by 25
“Most of its activities are dependent on the ability to activate or repress transcription (Farmer et al., 1992; Ginsberg et al., 1991; Kern et al., 1991; Seto et al., 1992; Zambetti et al., 1992).”
BackgroundRepression of Interleukin-2 and Interleukin-4 Promoters by Tumor Suppressor Protein p53
PESCH, J., Brehm, U., Staib, C., & Grummt, F. (1996) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1996.16.595 · Cited by 25
Saegusa, M., Takano, Y., Kishimoto, H., Wakabayashi, G., Nohga, K., & Okudaira, M. (1993) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01195346 · Cited by 24
“In addition, it was recently reported that wild-type p53 protein is directly capable of activating transcription but this activity is inhibited by interaction with mutant-type p53 protein (Farmer et al. 1992).”
BackgroundDamania, B., Mital, R., & Alwine, J. C. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1331 · Cited by 24
Chao, H. H., Buchmann, A. M., & DeCaprio, J. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7624-7633.2000 · Cited by 28
“The p53-binding domain of TAg binds to the specific DNA-binding domain of p53, thereby directly interfering with the ability of p53 to activate transcription (3, 21, 51).”
BackgroundPaz, K., Socci, N. D., van Nimwegen, E., Viale, A. J., & Darnell, J. E., Jr. (2004) · Oncogene · doi:10.1038/sj.onc.1207803 · Cited by 27
“Sometime later, p53, the product of a tumor suppressor gene, also proved to be a transcription factor (Kern et al., 1991; Farmer et al., 1992; Zambetti et al., 1992).”
BackgroundRoemer, K., & Friedmann, T. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb21718.x · Cited by 30
Gomes, N. P., & Espinosa, J. M. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12998 · Cited by 24
“First and foremost, p53 is a transcription factor.(11-13) Although some transcription-independent functions have been ascribed to this tumor suppressor,(14-19) its role as a transcriptional regulator accounts for most of its biological activity.”
BackgroundHDM2-Binding Partners: Interaction with Translation Elongation Factor EF1α
Frum, R. A., Busby, S. A., Ramamoorthy, M., Deb, S., Shabanowitz, J., Hunt, D. F., & Deb, S. P. (2007) · Journal of Proteome Research · doi:10.1021/pr060584p · Cited by 24
Sequence-specific interaction of a conformational domain of p53 with DNA.
Srinivasan, R., Roth, J. A., & Maxwell, S. A. (1993) · PubMed · Cited by 23
Oncogenes and onco-suppressor genes in lung cancer
Anderson, M. L., & Spandidos, D. A. (1993) · Respiratory Medicine · doi:10.1016/0954-6111(93)90066-9 · Cited by 23
Renolleau, S., Benjelloun, N., Ben‐Ari, Y., & Charriaut‐Marlangue, C. (1997) · APOPTOSIS · doi:10.1023/a:1026453623753 · Cited by 23
“Furthermore, during this time period, the p53 protein is translocated from the cytoplasm to the nucleus, suggesting that p53 can directly activate transcription from p53-binding sites.(33,34) In contrast, TUNEL-positive cells expressed both nuclear and cytoplasmic p53 immunoreactivity, at 9 h reperfusion.”
BackgroundXu, X., Zhang, J., Han, K., Zhang, Z., Chen, G., Zhang, J., Mao, X., & Cao, B. (2014) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21558 · Cited by 22
“The tumor suppressor protein p53 is another gatekeeper in the cell cycle progress by surveilling the G1 checkpoint [19].”
BackgroundHofmann, S., Mai, J., Masser, S., Groitl, P., Herrmann, A., Sternsdorf, T., Brack‐Werner, R., & Schreiner, S. (2020) · Advanced Science · doi:10.1002/advs.201902130 · Cited by 22
Telomerase Expression and p53 Status in Hepatocellular Carcinoma
Kobayashi, T., Sugawara, Y., Shi, Y.-Z., & Makuuchi, M. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05542-9 · Cited by 22
Cellular proteins involved in papillomavirus-induced transformation
Swan, D., Vernon, S. D., & Icenogle, J. P. (1994) · Archives of Virology · doi:10.1007/bf01310042 · Cited by 30
“Specific p53 DNA-binding sites have been identified and p53 has been shown to activate transcription adjacent to these sites [17].”
BackgroundGhosh, M., Huang, K., & Berberich, S. J. (2003) · Biochemistry · doi:10.1021/bi0271291 · Cited by 22
Molecular analysis for p53 and mdm2 in intracranial germ cell tumors
Iwato, M., Tachibana, O., Tohma, Y., Nitta, H., Hayashi, Y., & Yamashita, J. (2000) · Acta Neuropathologica · doi:10.1007/pl00007401 · Cited by 22
Cole, S. L., & Tevethia, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8420-8432.2002 · Cited by 22
“Binding of p53 to wild-type T antigen interferes with the ability of p53 to activate transcription (3, 15).”
Background
Metadata
- Authors
- Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C.
- Affiliations
- Columbia University (US)
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2063158632
- Cited by
- 579
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 7
- FWCI
- 38.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, transcriptional activation, wild-type p53, mutant p53, SV40 large T antigen, DNA-binding proteins, tumour suppressor, protein-protein interaction, transcriptional repression
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, DNA Mutational Analysis, DNA-Binding Proteins, Gene Expression Regulation, HeLa Cells, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Structure-Activity Relationship, Transcription Factors, Transcription, Genetic, Tumor Suppressor Protein p53, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.